Safety and efficacy of bevacizumab combined with R-CHOP regimen in seven Chinese patients with untreated diffuse large B-cell lymphoma

Cancer Cell International

Volumn 14, Issue 1, 2014, Pages

  Fu, Zhiying ^a   Zhu, Jun ^a   Zheng, Wen ^a   Liu, Weiping ^a   Ying, Zhitao ^a   Xie, Yan ^a   Wang, Xiaopei ^a   Lin, Ningjing ^a   Tu, Meifeng ^a   Ping, Lingyan ^a   Deng, Lijuan ^a   Zhang, Chen ^a   Ding, Ning ^a   Song, Yuqin ^a  

^a PEKING UNIVERSITY CANCER HOSPITAL AND INSTITUTE   (China)

Author keywords

Bevacizumab; DLBCL; Efficacy; Safety

Indexed keywords

BEVACIZUMAB; CYCLOPHOSPHAMIDE; DOXORUBICIN; PREDNISONE; RITUXIMAB; VINCRISTINE;

ADULT; ARTICLE; BLOOD TOXICITY; CANCER RADIOTHERAPY; CANCER SURVIVAL; CHINESE; CLINICAL ARTICLE; CONGESTIVE HEART FAILURE; DRUG EFFICACY; DRUG SAFETY; EPISTAXIS; FEMALE; GASTROINTESTINAL TOXICITY; GINGIVA BLEEDING; HUMAN; LARGE CELL LYMPHOMA; MAINTENANCE CHEMOTHERAPY; MALE; MIDDLE AGED; MULTIPLE CYCLE TREATMENT; OVERALL SURVIVAL; PROTEINURIA; SURVIVAL TIME; THROMBOCYTOPENIA; TREATMENT RESPONSE; TUMOR GROWTH; YOUNG ADULT;

EID: 84892462160     PISSN: None     EISSN: 14752867     Source Type: Journal    
DOI: 10.1186/1475-2867-14-5     Document Type: Article

References (26)

1. Ferlay J, Shin HR, Bray F, Forman D, Mathers C, Parkin DM. Estimates of worldwide burden of cancer in 2008. Int J Cancer 2010, 127:2293-2917.
2. Tilly H, Drey LM, ESMO Guidelines Working Group Diffuse large B-cell non-Hodgkin's lymphoma: ESMO clinical practice guidelines for diagnosis, treatment and follow-up. Ann Oncol 2010, 21:172-174. ESMO Guidelines Working Group.
3. Martelli M, Ferreri AJ, Agostinelli C, Di Rocco A, Pfreundschuh M, Pileri SA. Diffuse large B-cell lymphoma. Crit Rev Oncol Hematol 2013, 87(2):146-171. 10.1016/j.critrevonc.2012.12.009, 23375551.
4. Coiffier B, Thieblemont C, Van Den Neste E, Lepeu G, Plantier I, Castaigne S, Lefort S, Marit G, Macro M, Sebban C, Belhadj K, Bordessoule D, Fermé C, Tilly H. Long-term outcome of patients in the LNH-98.5 trial, the first randomized study comparing rituximab-CHOP to standard CHOP chemotherapy in DLBCL patients: a study by the Groupe d'Etudes des Lymphomes de l'Adulte. Blood 2010, 116(12):2040-2045. 10.1182/blood-2010-03-276246, 2951853, 20548096.
5. Pfreundschuh M, Schubert J, Ziepert M, Schmits R, Mohren M, Lengfelder E, Reiser M, Nickenig C, Clemens M, Peter N, Bokemeyer C, Eimermacher H, Ho A, Hoffmann M, Mertelsmann R, Trümper L, Balleisen L, Liersch R, Metzner B, Hartmann F, Glass B, Poeschel V, Schmitz N, Ruebe C, Feller AC, Loeffler M, German High-Grade Non-Hodgkin Lymphoma Study Group (DSHNHL) Six versus eight cycles of bi-weekly CHOP-14 with or without rituximab in elderly patients with aggressive CD20+ B-cell lymphomas: a randomized controlled trial (RICOVER-60). Lancet Oncol 2008, 9:105-116. 10.1016/S1470-2045(08)70002-0, 18226581, German High-Grade Non-Hodgkin Lymphoma Study Group (DSHNHL).
6. Pfreundschuh M, Kuhnt E, Trümper L, Osterborg A, Trneny M, Shepherd L, Gill DS, Walewski J, Pettengell R, Jaeger U, Zinzani PL, Shpilberg O, Kvaloy S, de Nully Brown P, Stahel R, Milpied N, López-Guillermo A, Poeschel V, Grass S, Loeffler M, Murawski N, MabThera InternationalTrial (MInT) Group CHOP-like chemotherapy with or without rituximab in young patients with good-prognosis diffuse large-B-cell lymphoma: 6-year results of an open-label randomised study of the MabThera International Trial Group. Lancet Oncol 2011, 2:1013-1022. MabThera InternationalTrial (MInT) Group.
7. Potti A, Ganti AK, Kargas S, Koch M. Immunohistochemical detection of C-kit (CD117) and vascular endothelial growth factor (VEGF) overexpression in mantle cell lymphoma. Anticancer Res 2002, 22:2899-2901.
8. Mori F, Ishida T, Ito A, Sato F, Masaki A, Takino H, Ri M, Kusumoto S, Komatsu H, Ueda R, Inagaki H, Iida S. Potent antitumor effects of bevacizumab in a microenvironment-dependent human lymphoma mouse model. Blood Cancer J 2012, 2(4):e67. 10.1038/bcj.2012.12, 3346682, 22829969.
9. Ruan J, Hajjar K, Rafii S, Leonard JP. Angiogenesis and antiangiogenic therapy in non-Hodgkin's lymphoma. Ann Oncol 2009, 20:413-424. 2733074, 19088170.
10. Stopeck AT, Bellamy W, Unger J, Rimsza L, Iannone M, Fisher RI, Miller TP. Phase II trial of single agent bevacizumab in patients with relapsed, aggressive non-Hodgkin's lymphoma (NHL): Southwest Oncology Group Study S0108. J Clin Oncol 2005, 23(16S):6592.
11. Stopeck AT, Unger JM, Rimsza LM, Bellamy WT, Iannone M, Persky DO, Leblanc M, Fisher RI, Miller TP. A phase II trial of single agent bevacizumab in patients with relapsed, aggressive non-Hodgkin lymphoma: Southwest Oncology Group Study S0108. Leuk Lymphoma 2009, 50:728-735. 10.1080/10428190902856808, 3532923, 19373598.
12. Ganjoo KN, An CS, Robertson MJ, Gordon LI, Sen JA, Weisenbach J, Li S, Weller EA, Orazi A, Horning SJ. Rituximab, bevacizumab and CHOP (RA-CHOP) in untreated diffuse large B cell lymphoma: Safety, biomarker and pharmacokinetic analysis. Leuk Lymphoma 2006, 47:998-1005. 10.1080/10428190600563821, 16840188.
13. WHO Classification of Tumours of Haematopoietic and Lymphoid Tissue. International Agency for Research on Cancer 2008, Geneva, Switzerland: World Health Organization, Swerdlow S, Campo E, Harris NL.
14. Cheson BD, Horning SJ, Coiffier B, Shipp MA, Fisher RI, Connors JM, Lister TA, Vose J, Grillo-López A, Hagenbeek A, Cabanillas F, Klippensten D, Hiddemann W, Castellino R, Harris NL, Armitage JO, Carter W, Hoppe R, Canellos GP. Report of an international workshop to standardize response criteria for non-Hodgkin's lymphomas. J Clin Oncol 1999, 17:2351-2352.
15. Common Terminology Criteria for Adverse Events v3.0 (CTCAE) 2006, : , http://ctep.cancer.gov/protocolDevelopment/electronic_applications/docs/ctcaev3.pdf Accessed July 30, 2013.
16. Geiger-Gritsch S, Stollenwerk B, Miksad R, Guba B, Wild C, Siebert U. Safety of bevacizumab in patients with advanced cancer:a meta-analysis of randomized controlled trial. Oncologist 2010, 15(12):1179-1191. 3227908, 21045188.
17. Ganjoo K, Hong F, Horning SJ, Gascoyne RD, Natkunam Y, Swinnen LJ, Habermann TM, Kahl BS, Advani RH. Bevacizumab and CHOP (a-CHOP) in combination for patients with peripheral T-cell or natural killer cell neoplasms: an Eastern Cooperative group study (E2404). Leuk Lymphoma in press.
18. Stopeck AT, Unger JM, Rimsza LM, LeBlanc M, Farnsworth B, Iannone M, Glenn MJ, Fisher RI, Miller TP. A phase 2 trial of standard-dose cyclophosphamide, doxorubicin, vincristine, prednisone (CHOP) and rituximab plus bevacizumab for patients with newly diagnosed diffuse large B-cell non-Hodgkin lymphoma: SWOG 0515. Blood 2012, 120:1210-1217. 10.1182/blood-2012-04-423079, 3418716, 22734071.
19. Hapani S, Sher A, Chu D, Wu S. Increased risk of serious hemorrhage with bevacizumab in cancer patients: a meta-analysis. Oncology 2010, 79:27-38. 10.1159/000314980, 21051914.
20. Miles D. Management of toxicity in patients receiving therapy with bevacizumab. EJC 2008, 6:9-39.
21. Wu S, Kim C, Baer L, Zhu X. Bevacizumab increases risk for severe proteinuria in cancer patients. J Am Soc Nephrol 2010, 21:1381-1389. 10.1681/ASN.2010020167, 2938590, 20538785.
22. Eremina V, Jefferson JA, Kowalewska J, Hochster H, Haas M, Weisstuch J, Richardson C, Kopp JB, Kabir MG, Backx PH, Gerber HP, Ferrara N, Barisoni L, Alpers CE, Quaggin SE. VEGF inhibition and renal thrombotic microangiopathy. N Eng J Med 2008, 358(11):1129-1136.
23. Cheng H, Force T. Molecular mechanisms of cardiovascular toxicity of targeted cancer therapeutics. Circ Res 2010, 106(1):21-34. 10.1161/CIRCRESAHA.109.206920, 20056943.
24. Kamba T, McDonald DM. Mechanisms of adverse effects of anti-VEGF therapy for cancer. Br J Cancer 2007, 96(12):1788-1795. 10.1038/sj.bjc.6603813, 2359962, 17519900.
25. Vaklavas C, Lenihan D, Kurarock R, Tsimberidou AM. Anti-vascular endothelial growth factor therapies and cardiovascular toxicity: what are the important clinical markers to target?. Oncologist 2010, 15:130-141. 10.1634/theoncologist.2009-0252, 3227935, 20139170.
26. Hawkes EA, Okines AF, Plummer C, Cunningham D. Cardiotoxicity in patients treated with bevacizumab is potentially reversible. J Clin Oncol 2011, 29:560-562.